Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANT-045
- Development stage
- Preclinical
- Lead developer
- Antikor Biopharma
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ANT-045 is an investigational Functional Drug Conjugate (FDC) developed by Antikor Biopharma that targets cMET-expressing cells in solid tumors, with a particular focus on gastrointestinal cancers. Utilizing Antikor's proprietary OptiLink technology platform, ANT-045 employs a small antibody fragment (scFv) rather than a full-length monoclonal antibody, allowing for a high drug-to-antibody ratio (DAR). This fragment-based design is intended to facilitate superior tumor penetration and faster systemic clearance compared to conventional antibody-drug conjugates (ADCs), potentially expanding the therapeutic window. Preclinical data have demonstrated picomolar in vitro potency and significant in vivo efficacy across various cMET expression levels (high, medium, and low), alongside a favorable safety profile in non-human primate studies. The drug is currently progressing toward IND-filing.
- Other names
- Antikor cMET FDCOptiLinked cMET ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on ANT-045.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANT-045.